MediGene AG's Drug Veregen® Launched In Canada

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Martinsried/Munich, July 17, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces the launch of its drug Veregen® (Sinecatechins Ointment, 10%) for the treatment of genital warts in Canada through the marketing partner Paladin Labs Inc. (who acquired Triton Pharma). Within the scope of the license agreement, Medigene receives sales milestone payments as well as royalties on Veregen® sales.

Up to now, Veregen® is available in the USA, in 15 European countries (Germany, Austria, Switzerland, Spain, Serbia, the Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Czech Republic, Slovakia, Hungary, and Poland), and in Taiwan. The drug has obtained market approval in a number of additional countries. Several marketing partnership agreements have been concluded in Europe, Asia, and America.

About Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Sinecatechins 10% & 15% Ointment (Veregen®) has been included in the 2012 European Guideline for the Management of Anogenital Warts. In addition, in its current Sexually Transmitted Diseases Treatment Guidelines, the US Centers for Disease Control and Prevention includes Sinecatechins 15% Ointment (Veregen®) as a possible option for treating genital warts.

About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for Canadian and select emerging markets. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies. Paladin is an operating company of Endo International plc, a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Learn more at .

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit .

Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

Help employers find you! Check out all the jobs and post your resume.

Back to news